All In MedTech

FDA Clearance Tracker · P030031-S143

VISITAG SURPOINT™ External Processing Unit (“EPU”); CARTO 3 System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030031-S143
Device name
VISITAG SURPOINT™ External Processing Unit (“EPU”); CARTO 3 System
Applicant location
Irvine, CA
Received
Apr 1, 2026
Decided
Jun 30, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030031

Device type

Device class
Class III

Every decision under product code OAD

FDA's approval statement

As written in FDA's record.

approval for the Connection Interface Unit (CIU) to be used with the TRUPULSE™ Generator, to introduce a predetermined change control plan (PCCP) (Predetermined Change Control Plan TRUPULSE™ Generator System Version 1.0) for planned hardware and software changes to the TRUPULSE™ Generator and related labeling updates

Source documents

Other decisions for Biosense Webster, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.